Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Short Interest Update

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totaling 369,209 shares, a growth of 92.0% from the December 15th total of 192,269 shares. Based on an average daily trading volume, of 98,361 shares, the short-interest ratio is presently 3.8 days. Approximately 9.1% of the shares of the company are short sold. Approximately 9.1% of the shares of the company are short sold. Based on an average daily trading volume, of 98,361 shares, the short-interest ratio is presently 3.8 days.

Coeptis Therapeutics Price Performance

Shares of Coeptis Therapeutics stock traded down $0.07 during midday trading on Thursday, hitting $14.07. 39,117 shares of the company were exchanged, compared to its average volume of 49,350. The firm has a 50 day simple moving average of $15.37 and a 200-day simple moving average of $13.84. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.21 and a quick ratio of 2.21. The firm has a market cap of $75.11 million, a P/E ratio of -4.92 and a beta of -0.50. Coeptis Therapeutics has a 52 week low of $6.26 and a 52 week high of $21.41.

Coeptis Therapeutics (NASDAQ:COEP) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.58) earnings per share for the quarter. The business had revenue of $0.24 million during the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Coeptis Therapeutics in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Coeptis Therapeutics currently has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Coeptis Therapeutics stock. Yorkville Advisors Global LP acquired a new stake in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 8,000 shares of the company’s stock, valued at approximately $140,000. Coeptis Therapeutics comprises approximately 0.0% of Yorkville Advisors Global LP’s investment portfolio, making the stock its 24th biggest position. Yorkville Advisors Global LP owned about 0.17% of Coeptis Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 13.88% of the company’s stock.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.